The correct name for Doxazosin Extended-Release Tablets is Doxazosin Mesylate Extended-Release Tablets. Doxazosin is a selective alpha 1 receptor inhibitor. In humans, it counteracts phenylephrine prostate contraction, which can lower peripheral vascular resistance and thus blood pressure. Side effects of this product include respiratory or urinary tract infections, headache and dizziness, palpitations, hypotension, cough, bronchitis, and dyspnea. Doxazosin Mesylate Extended-Release Tablets are indicated for the symptomatic treatment of benign prostatic hyperplasia or for the treatment of hypertension. It is contraindicated in patients who are allergic to doxazosin, quinazolines, or any of the ingredients contained in this product, in those who have had a recent myocardial infarction, and in those who have a history of gastrointestinal obstruction, esophageal obstruction, or any degree of narrowing of the luminal diameter of the gastrointestinal tract. Doxazosin Mesylate Extended-Release Tablets should be swallowed whole and should not be chewed, broken or crushed. If you need to use this drug, please consult a medical professional, follow the doctor’s instructions and use the drug wisely.